Keywords: nxl104/ceftazidime, enters, ph, ii, cuti, trial, french
NXL104/ceftazidime enters Ph II cUTI trial
Article | 17 November 2008
French antibiotics developer Novexel says that its most advanced injectable antibacterial, which combines its broad-spectrum beta-lactamase inhibitor, NXL104, with the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
